Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy

American Journal of Physiology-Heart and Circulatory Physiology 2026 Open access

Read full text
Authors: Kelsey Muir, Christopher R Stone, Dwight D. Harris, Meghamsh Kanuparthy, Mark Broadwin, Jad Hamze, Jun Feng, Frank W Sellke
DOI: 10.1152/ajpheart.00828.2025
Cited by: 2
References: 62

Abstract

In a clinically relevant swine model of chronic ischemic cardiomyopathy, oral semaglutide improved ventricular performance, likely through enhanced coronary collateralization. This benefit holds particular promise for patients with obesity and type 2 diabetes-populations already eligible for GLP-1 analog therapy. These findings support the initiation of randomized clinical trials of early GLP-1R agonist use at the time of CAD diagnosis to assess long-term outcomes and potential incorporation into standard ischemic heart disease management.

Fields of Study & Subjects

Diabetes Treatment and Management Cardiovascular Function and Risk Factors Cardiovascular Disease and Adiposity

Publication details

Journal / source
American Journal of Physiology-Heart and Circulatory Physiology
Publisher
American Physiological Society
Volume
330
Issue
3
Pages
H651–H663
Publication date
19 January 2026
Language
EN